NCT05877053View on ClinicalTrials.gov

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

May 9, 2023

Primary Completion Date

November 20, 2024

Study Completion Date

November 20, 2024

Conditions
Healthy Participants
Interventions
DRUG

CK-4021586

CK-4021586

DRUG

Placebo for CK-4021586

Placebo for CK-4021586

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

Cytokinetics
All Listed Sponsors
lead

Cytokinetics

INDUSTRY

NCT05877053 - A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants | Biotech Hunter | Biotech Hunter